0000000000211469

AUTHOR

Tanya B. Dorff

showing 3 related works from this author

Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression

2016

SummaryImmune system defects are at the center of aging and a range of diseases. Here, we show that prolonged fasting reduces circulating IGF-1 levels and PKA activity in various cell populations, leading to signal transduction changes in long-term hematopoietic stem cells (LT-HSCs) and niche cells that promote stress resistance, self-renewal, and lineage-balanced regeneration. Multiple cycles of fasting abated the immunosuppression and mortality caused by chemotherapy and reversed age-dependent myeloid-bias in mice, in agreement with preliminary data on the protection of lymphocytes from chemotoxicity in fasting patients. The proregenerative effects of fasting on stem cells were recapitula…

0301 basic medicinemedicine.medical_specialtyhematopoietic regenerationfastingmedicine.medical_treatmentCellBiologyMice03 medical and health sciences0302 clinical medicineImmune systemSettore BIO/13 - Biologia ApplicataInternal medicinemedicineGeneticsAnimalsRegenerationInsulin-Like Growth Factor I030304 developmental biologyImmunosuppression Therapy0303 health sciencesstem cells; fasting; nutrition; hematopoietic regenerationRegeneration (biology)Hematopoietic stem cellImmunosuppressionCell BiologyHematopoietic Stem CellsCyclic AMP-Dependent Protein Kinases3. Good healthCell biologyMice Inbred C57BLstem cellHaematopoiesisEndocrinologynutrition030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisMolecular MedicineSignal transductionStem cellCell Stem Cell
researchProduct

A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan

2015

SummaryProlonged fasting (PF) promotes stress resistance, but its effects on longevity are poorly understood. We show that alternating PF and nutrient-rich medium extended yeast lifespan independently of established pro-longevity genes. In mice, 4 days of a diet that mimics fasting (FMD), developed to minimize the burden of PF, decreased the size of multiple organs/systems, an effect followed upon re-feeding by an elevated number of progenitor and stem cells and regeneration. Bi-monthly FMD cycles started at middle age extended longevity, lowered visceral fat, reduced cancer incidence and skin lesions, rejuvenated the immune system, and retarded bone mineral density loss. In old mice, FMD c…

MaleAbdominal Fat; Adult; Aged; Aging; Animals; Body Weight; Cardiovascular Diseases; Diet; Female; Humans; Male; Mice; Mice Inbred C57BL; Middle Aged; Neoplasms; Neurogenesis; Pilot Projects; Psychomotor Performance; Regeneration; Saccharomyces cerevisiae; Young Adult; Cognition; Fasting; LongevityAgingPhysiologyPilot ProjectsMiceCognitionNeoplasmsCardiovascular DiseaseSettore MED/49 - Scienze Tecniche Dietetiche Applicatemedia_common2. Zero hungerNeurogenesisLongevityFastingMiddle Aged3. Good healthCardiovascular DiseasesFemaleStem cellHumanAdultmedicine.medical_specialtyNeurogenesismedia_common.quotation_subjectLongevityAbdominal FatSaccharomyces cerevisiaeBiologyArticleYoung AdultImmune systemInternal medicineDiabetes mellitusmedicineAnimalsHumansRegenerationPilot ProjectAdverse effectCell Biology; Molecular Biology; PhysiologyMolecular BiologyAgedAnimalBody WeightCell Biologymedicine.diseaseMiddle ageDietMice Inbred C57BLEndocrinologyCancer cellNeoplasmNeurogenesiPsychomotor Performance
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct